In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
|Articles|November 23, 2021
Daily Medication Pearl: Tavneos (avacopan) for Severe Active Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Author(s)Saro Arakelians, PharmD
Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a.
Advertisement
Indication: Tavneos is a complement 5a receptor (C5aR) antagonist indicated as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
Insight:
- Dosing:The recommended dosage is 30 mg (three 10 mg capsules) twice daily, with food.
- Dosage form: 10 mg capsules
- Adverse events: The most common adverse reactions (≥5%) include nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, and paresthesia.
- Mechanism of action:Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a. Avacopan blocks C5a-mediated neutrophil activation and migration.
- Manufacturer: ChemoCentryx
References
- Approval Information. Tavneos (Avacopan); ChemoCentryx. October 2021. Accessed November 22, 2021.
https://www.chemocentryx.com/wp-content/uploads/2021/10/FINAL-PI-and-Med-Guide-7-Oct-21.pdf - Tavneos Physician Website. Chemocentryx. Accessed November 22, 2021.
https://tavneos.com/hcp/?gclid=EAIaIQobChMIkI659bei9AIVIiCtBh0ywAUpEAAYASAAEgJvTfD_BwE - ChemoCentryx Taneos US FDA Approval. ChemoCentryx; October 8, 2021. Accessed November 22, 2021.
https://ir.chemocentryx.com/static-files/2803ef08-be6b-4000-9975-0a02abe1b5a1
Advertisement
Related to this article
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Semaglutide Normalized Liver Fat in Most Adults With Obesity
2
Reframing Statins and Brain Health Around Stroke Prevention
3
mRNA Reenters the Mainstream
4
Phase 3 Trial Finds Adding Monoclonal Antibody to mRNA Vaccine Improves COVID-19 Immunization Tolerability
5